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Background and objective: Transbronchial needle aspiration procedures (TBNA, EBUS-TBNA) in
sarcoidosis are associated with better results in stage I, and are preferentially performed in
three lymph node stations (4R, 7, 11) as well as in the right mediastinal stations. We hypoth-
esized that CT characteristics of lymphadenopathy, which were never systematically evalu-
ated in untreated patients undergoing bronchoscopy for suspected sarcoidosis, could help
explain the pattern of sampling and the different yield by radiographic stage of TBNA and
EBUS-TBNA.
Methods: Number, size and location of lymph nodes were recorded in 74 consecutive sarcoi-
dosis patients referred for biopsy, and were correlated with the radiographic stage.
Results: The mean number of stations harboring enlarged nodes was 8.05 per patient. Lymph-
adenopathy was more common in stations 7 (98.6% of patients), 11R (97.3%), 11L (86.5%), and
4R (79.7%). The overall mean size was 14.39 mm, but the largest mean size was documented in
stations 7 (17.57 mm), 11R (16.83 mm), 8R (16.02 mm), and 4R (15.19 mm). The median [IQR]
number of enlarged lymph node stations was significantly higher in the right than in the left
mediastinum (2 [1e2] versus 0 [0e1], p < 0.001). No relationship was found between lymph-
adenopathy and sarcoidosis stage.1 6478804; fax: þ39 051 6478727.
usl.bologna.it (R. Trisolini), anevlavis@yahoo.com (S. Anevlavis), ctinelli@smatteo.pv.it (C. Tinelli),
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seen in stations (A) #4R (12.15 mm),
#7 (19.71 mm), #11L (12.99 mm); (D
was found, as an incidental findingConclusions: The CT pattern of thoracic lymphadenopathy helps explain the excellent yield
and the pattern of sampling of TBNA and EBUS-TBNA in sarcoidosis, but does not explain
the higher yield associated with these procedures in stage I.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Transbronchial needle aspiration procedures (TBNA and
EBUS-TBNA) from hilar and mediastinal lymph nodes have
become the first-step method for the pathological con-
firmation of sarcoidosis because of their safety and their
superiority as compared to conventional endoscopic sam-
pling methods (broncoalveolar lavage, endobronchial bi-
opsy and transbronchial biopsy).1e5 Beyond the very high
success rate, three findings characterized most literature
studies that evaluated the role of TBNA and EBUS-TBNA in
sarcoidosis. First, the diagnostic yield of these procedures
proved constantly higher in stage I than in stage II, by a rate
ranging from 7% to 36%.2e6 Second, the vast majority of the
aspirations were performed in only 3 lymph node stations
(4R, 7, 11), even in trials where EBUS-TBNA was tested.1e10
Third, the right mediastinal stations were more frequently
targeted than the left ones, by far.1e6
The main characteristics (number, size and location) of
lymph nodes at computed tomography, and their possiblef the chest (axial view) from a
#4L (13.77 mm), #5 (17.53 mm)
) #8R (17.20 mm), #12L (14.40
, in the pulmonary artery for ridifferences according to the disease stage, could theoret-
ically help explain the pattern of sampling and some specific
results (e.g. higher yield in stage I) associated with TBNA and
EBUS-TBNA in untreated patients undergoing biopsy for sus-
pected sarcoidosis. Unfortunately, only two trials dating
back at the ’90s were specifically designed to assess the CT
pattern of thoracic lymphadenopathy in sarcoidosis, to our
knowledge.11,12 These two trials provided interesting data,
but they enrolled both treated and untreated patients at any
time during the disease course. Furthermore, they were
small-sized (25 and 40 patients), did not report the size of the
lymphadenopathy, did not exclude studies lacking contrast
enhancement, and used different lymph node maps to
describe the lymph node location.11,12
The aim of the present study was to assess if the CT
characteristics (size, location, number) of thoracic lymph-
adenopathy in untreated patients undergoing bronchoscopy
for suspected sarcoidosis could help explain the pattern of
sampling and some specific results (e.g. higher yield in
stage I) of TBNA and EBUS-TBNA in sarcoidosis.52-yr-old male sarcoidosis patient. Enlarged lymph nodes are
; (B) # 10R (15.05 mm), # 12 L (14.17 mm); (C) #11R (20.55 mm),
mm). An intravascular filling defect consistent with an embolus
ght lower lobe (panel D, arrow).
Table 2 Frequency and size of lymph node involvement
according to the lymph node location.
Lymph node
station
Frequency of
involvement
Size, mm
Mean SD
# 1 3/74 (4%) 16.38 6.20
# 2R 22/74 (29.7%) 12.69 2.87
# 2L 1/74 (1.3%) 10.93 NA
# 3a 6/74 (8.1%) 11.79 1.76
# 3p 10/74 (13.5%) 11.76 1.61
# 4R 59/74 (79.7%) 15.19 4.48
# 4L 31/74 (41.9%) 13.37 2.90
# 5 29/74 (39.2%) 14.33 3.69
# 6 15/74 (20.3%) 13.07 2.42
# 7 73/74 (98.6%) 17.57 5.27
# 8R 52/74 (70.3%) 16.02 4.49
# 8L 7/74 (9.5%) 13.73 2.26
# 9R 5/74 (6.8%) 13.54 3.77
# 9L 0/74 (0%) NA NA
# 10R 40/74 (54%) 13.64 2.91
# 10L 39/74 (52.7%) 13.24 2.20
# 11R 72/74 (97.3%) 16.83 3.89
# 11L 64/74 (86.5%) 13.60 2.69
# 12R 26/74 (35.1%) 14.38 3.90
# 12L 42/74 (56.7%) 14.07 2.30
NA: not applicable.
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Study design and study population
This is a retrospective study whose protocol was approved
by the Ethics Committee of the Azienda USL di Bologna
(Prot. No. 803/CE). The files of the Interventional Pulmo-
nology Unit of Maggiore Hospital (Bologna, Italy) were
searched for all patients referred for the pathologic con-
firmation of clinically suspected sarcoidosis over a 3-year
period (January 1, 2009 to December 31, 2011). Patients
were included if they were 18 years or older, had sarcoi-
dosis pathologically confirmed at the end of the diagnostic
work-up, and had a contrast-enhanced CT of the chest
performed before bronchoscopy. Patients were excluded if
they had been given steroids or immunosuppressive drugs in
the 4 weeks before bronchoscopy, as wel as if the CT they
underwent before bronchoscopy was non-enhanced or was
unavailable in electronic format (conditions not compatible
with a reliable assessment of size, number and location of
thoracic lymph nodes).
Procedures
A radiologist (P.O) and an interventional pulmonologist
(R.T) jointly reviewed the contrast-enhanced CT of the
chest of each patient enrolled in the study, and systemat-
ically recorded location and size of enlarged lymph nodes,
as well as the number of stations harboring enlarged lymph
nodes. The lymph node map recently proposed by the In-
ternational Association for the Study of Lung Cancer was
used to define the lymph node location.13 Lymph nodes
were considered enlarged by CT criteria if they were larger
than 1 cm on their short axis. If more than one node >1 cm
was present in the same station, the largest one was used
for the statistical analysis. Possible disagreements between
the examiners were resolved by consensus. Possible corre-
lations between the characteristics of lymphadenopathy
and sarcoiodosis stage, age, and sex were evaluated.
Statistical analysis
The ShapiroeWilk test was used to test the normal distri-
bution of quantitative variables. The results were
expressed as mean values and standard deviation (SD), and
95% Confidence Interval were reported, as appropriate.
Student t-test or ManneWhitney test (if variables were all
not normally distributed) were used to analyze differences
between gender or sarcoidosis stage. Chi-square or Fisher
exact test were used to test differences between qual-
itative variables. A p < 0.05 was considered statisticallyTable 1 Mean number of enlarged LN stations according to sar
Stage I Stage II
All LNs 8.20 (7.39e9.02) 7.83 (6.70e8.97) p Z
Mediastinal LNs 4.13 (3.61e4.66) 4.35 (3.64e5.06) p Z
Hilar LNs 4.06 (3.56e4.57) 3.48 (2.86e4.10) p Z
a Results are expressed as mean and (95% CI).significant. All tests were two-sided. Data analysis was
performed using the STATA statistical package (version 12;
Stata Corporation, College Station, 2011, Texas, USA).
Results
Eighty-two patients fulfilled the inclusion criteria, but eight
of them were excluded from the analysis for the following
reasons: CT performed without contrast enhancement (4
patients), CT unavailable in electronic format (3 patients),
and steroid treatment ongoing at the time of CT (1 patient).
The main demographics of the 74 patients included in the
analysis were a median [IQR] age of 45 [36e55] years,
a male to female ratio of 1.05 (38/36), and a stage I to
stage II ratio of 1.38 (43/31). Seventy-three patients were
white, and one was black.
The mean (SD) number of all (mediastinal þ hilar) sta-
tions harboring enlarged lymph nodes was 8.05 (2.83),
whereas the mean (SD) number of mediastinal and hilar
enlarged lymph node stations was 4.22 (1.80) and 3.82
(1.67), respectively. A combination of hilar and mediastinal
lymphadenopathy was seen in 72 of 74 patients (97%)coidosis stage and sex.a
Male Female
0.58 8.26 (7.43e9.09) 7.83 (6.76e8.89) p Z 0.51
0.61 4.26 (3.76e4.77) 4.19 (3.49e4.89) p Z 0.87
0.13 4.28 (3.43e4.57) 3.63 (3.10e4.19) p Z 0.36
Figure 2 Contrast-enhanced CT of the chest (axial view) from 4 different sarcoidosis patients. Uncommon locations for
lymphadenopathy in sarcoidosis (arrows) are stations #1 (A); #2L (B), #3a (C), and 8L (D).
Figure 3 Contrast-enhanced CT of the chest (axial view) from 4 different sarcoidosis patients. Multiple lymph nodes are evident
in stations #2R (A), #2L (B), #4R (C), and 7 (D).
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in the remaining 2 patients. The mean number of stations
with enlarged nodes was similar regardless of age (data not
shown), sex, and sarcoidosis stage (Table 1).
Stations number 7 (98.6% of patients), 11R (97.3%), 11L
(86.5%), and 4R (79.7%) were the most common location for
lymphadenopathy (Table 2). Interestingly, lymph nodes in
the above stations were frequently simultaneously enlarged
(Fig. 1AeC). In particular, lymph nodes in stations 7 þ 4R
were simultaneously enlarged in 78.4% of patients, lymph
nodes in stations 4R þ 11 (R/L) in 71.6%, lymph nodes in
stations 7 þ 11 (R/L) in 85.1%, and lymph nodes in stations
4R þ 7 þ 11 (R/L) in 70.3%. Lymphadenopathy in stations
number 1 (4% of patients), 2L (1.3%), 3a (8.1%), 8L (9.5%),
and 9 (6.8%) was uncommon (Fig. 2AeC). The median [IQR]
number of enlarged lymph nodes was significantly higher in
the right than in the left mediastinal stations (2 [1e2]
versus 0 [0e1], p < 0.001). The presence of several
enlarged nodes in the same lymph node station was quite
common (Fig. 3AeC), and a continuum of enlarged nodes
without clear-cut separation between adjacent stations
was frequent as well (Fig. 4). No association was seen be-
tween any single lymph node station and sex, sarcoidosis
stage, and age (data not shown).
The overall mean (SD) lymph node size was 14.39
(2.14) mm (Table 2), but the mean size of lymph nodes in
stations number 7 (17.57 mm), 11R (16.83 mm), 8R
(16.02 mm), and 4R (15.19 mm) was larger (Table 2). TheFigure 4 Contrast-enhanced CT of the chest (sagittal view)
from a 41-yr-old female sarcoidosis patient showing a contin-
uum of lymph nodes in the right paratracheal area (stations
#2R through #4R, white arrow) and in the subcarinal area
(stations #7 through #8R, black arrow). A long lymph node in
the anterior mediastinum (station 3, red arrow) is also visible.mean size of enlarged lymph nodes was similar regardless of
age (data not shown), sex, and sarcoidosis stage (Table 3).Discussion
The first key characteristic of thoracic lymphadenopathy we
observed at CT in our series of untreated sarcoidosis patients
undergoing bronchoscopy for pathologic confirmation was the
simultaneous involvement of several mediastinal and hilar
stations in the vastmajority (97%) of them.11,12 Amean (SD) of
8.05 (2.83) lymph node stations per patient were, in fact,
enlarged in the present series. The availability of multiple
stations harboring enlargednodes is crucial for the endoscopic
diagnosis of sarcoidosis, as the number of stations sampledhas
been shown to influence the success rate of both TBNA and
EBUS-TBNA in this setting. In a study aimed at evaluating the
factors possibly predicting the yield of TBNA in sarcoidosis,
Trisolini et al. demonstrated that the number of lymph node
stations sampled was the only factor able to influence the
diagnostic yield.2 In particular, sampling of two lymph node
stations versus one was the only variable significantly asso-
ciated with a likelihood of a sarcoidosis-positive aspirate or
biopsy in both univariate (odds ratio 0.15, 95% CI 0.02e0.79)
andmultivariate (odds ratio0.12,95%CI 0.02e0.70) analyses.2
An indirect confirmation of this observation came subse-
quently from the randomized trial that demonstrated the su-
periority of EBUS-TBNA versus conventional TBNA in
sarcoidosis.14 In this study, the diagnostic yield on a per lymph
node basis and on a per-station basis was not significantly
different between conventional TBNA and EBUS-TBNA, and
the Authors hypothesized that the true reason for the higher
success rate of EBUS-TBNA over conventional TBNA was its
ability to identify and sample a higher number of lymph node
stations per patient (4 versus 2.2 respectively; p < 0.05).14
As for the distribution of enlarged lymph nodes, not only
stations considered endoscopically “easy-to-access” (4R, 7,
11) were the most commonly involved in our series (Table
2), but the simultaneous involvement of these stations
was very common as well (Fig. 1). Lymph nodes in stations
4R, 7, 11R and 11L were enlarged in 79.7%, 98.6%, 97.3%,
and 86.5% of patients, respectively, and the simultaneous
involvement of all these stations was found in 70.3% of
patients. These figures help explain why the majority of
aspirates (65%e100%) were obtained from stations 4R, 7,
and 11 in all the literature studies that evaluated the role
of TBNA and EBUS-TBNA in sarcoidosis.1e10 The frequent
involvement of stations 4R and 7 is of particular importance
for conventional TBNA, which being a “blind” procedure,
performs much better in these 2 stations due to the close
proximity of the useful landmark represented by the main
carina.15e17 Curiously, we could confirm the observation,
already made in previous studies,11,12 regarding the asym-
metry of the involvement of mediastinal lymph nodes in
sarcoidosis. Lymph nodes belonging to stations number 2, 4,
and 8 were, in fact, more commonly enlarged on the right
side than on the left one (Table 2). This observation pro-
vides a plausible explanation for the fact that the right
mediastinal stations were constantly more commonly tar-
geted than their left counterpart in literature studies
evaluating the role of TBNA and EBUS-TBNA in
sarcoidosis.1e10
Table 3 Mean size of enlarged lymph nodes according to sarcoidosis stage and sex.a
Stage I Stage II Male Female
All LNs 14.32 (13.71e14.93) 14.51 (13.63e15.38) p Z 0.72 14.60 (13.90e15.30) 14.18 (13.45e14.92) p Z 0.41
Mediastinal LNs 14.40 (13.61e15.18) 14.67 (13.58e15.76) p Z 0.67 14.78 (13.88e15.69) 14.22 (13.31e15.13) p Z 0.38
Hilar LNs 14.17 (13.67e14.68) 14.41 (13.53e15.29) p Z 0.61 14.49 (13.82e15.16) 14.05 (13.39e14.71) p Z 0.34
a Results are expressed as mean and (95% CI).
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size of thoracic lymphadenopathy in patients undergoing bi-
opsy for suspected sarcoiodosis, as no previous study eval-
uated this aspect.11,12 Literature trials evaluating the role of
transbronchial (TBNA and EBUS-TBNA) or transesophageal
(EUS-NA) needle aspiration procedures in sarcoidosis pro-
vided, in fact, only the mean size of the lymph nodes that
were biopsied.1e10,17e20 The results of the present study
suggest that the overall mean size of enlarged lymph node is
quite smaller than the mean size of the lymph nodes that are
usually sampled for diagnostic purposes. We recorded an
overall mean lymph node size of 14.39 mm, but we also
noticed that themean size of the lymphnodes that areusually
sampled was quite larger. The mean size of nodes in stations
number 7 (17.57 mm), 4R (15.19 mm), and 11R (16.83 mm),
was, in fact, larger than the overall mean lymph node size.
The large size, along with the common involvement of these
“easy-to-access” stations, provide more of a plausible
explanation for the excellent yields obtained by the endo-
scopic procedures that target themediastinum in sarcoidosis.
Age, sex, or disease stage did not influence the CT
pattern of lymphadenopathy in the sarcoidosis patients of
the present series. The lack of significant differences in the
main characteristics (size, location, number) of enlarged
nodes according to the sarcoidosis stage, in particular,
tends to rule out the hypothesis that the higher yield con-
stantly obtained by the endoscopic needle aspiration pro-
cedures in stage I of the disease could be explained by the
CT pattern of lymphadenopathy. It seems more likely that
a higher density of granulomas in lymph nodes of stage I
patients could explain these results. Interestingly, the
density of granulomas in lung tissue of sarcoidosis patients
has been used to explain differences in the yield of trans-
bronchial lung biopsy by radiographic stage. Burke and
colleagues, in particular, found that the density of granu-
lomas in transbronchial lung biopsy specimens was sig-
nificantly higher in stage II and III than in stage I.21
In conclusion, the CT pattern of thoracic lymphadenop-
athy in sarcoidosis is characterized by multiple lymph node
enlargements, larger size and more frequent involvement
of endoscopically “easy-to-access” stations (4R, 7, 11) and
predominant involvement of the right mediastinal stations.
These CT findings help explain the excellent yield and the
pattern of sampling of TBNA and EBUS-TBNA in sarcoidosis,
but do not explain the higher yield constantly obtained by
these procedures in stage I.Conflicts of interest statement
None of the authors of the manuscript has any financial,
personal, academic and/or intellectual conflict of interest.
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